nodes	percent_of_prediction	percent_of_DWPC	metapath
Felbamate—GRIN2A—Unblocking of NMDA receptor, glutamate binding and activation—ACTN2—dilated cardiomyopathy	0.0268	0.0738	CbGpPWpGaD
Felbamate—GRIN2A—CREB phosphorylation through the activation of CaMKII—ACTN2—dilated cardiomyopathy	0.0268	0.0738	CbGpPWpGaD
Felbamate—GRIN2A—Ras activation uopn Ca2+ infux through NMDA receptor—ACTN2—dilated cardiomyopathy	0.0245	0.0675	CbGpPWpGaD
Felbamate—GRIN2B—CREB phosphorylation through the activation of CaMKII—ACTN2—dilated cardiomyopathy	0.0228	0.0627	CbGpPWpGaD
Felbamate—GRIN2B—Unblocking of NMDA receptor, glutamate binding and activation—ACTN2—dilated cardiomyopathy	0.0228	0.0627	CbGpPWpGaD
Felbamate—GRIN2B—Ras activation uopn Ca2+ infux through NMDA receptor—ACTN2—dilated cardiomyopathy	0.0209	0.0574	CbGpPWpGaD
Felbamate—Antinuclear antibody positive—Lisinopril—dilated cardiomyopathy	0.02	0.0314	CcSEcCtD
Felbamate—GRIN2A—CREB phosphorylation through the activation of Ras—ACTN2—dilated cardiomyopathy	0.0175	0.0481	CbGpPWpGaD
Felbamate—Bullous eruption—Furosemide—dilated cardiomyopathy	0.0153	0.0241	CcSEcCtD
Felbamate—GRIN2B—CREB phosphorylation through the activation of Ras—ACTN2—dilated cardiomyopathy	0.0149	0.0409	CbGpPWpGaD
Felbamate—GRIN2A—Post NMDA receptor activation events—ACTN2—dilated cardiomyopathy	0.0144	0.0396	CbGpPWpGaD
Felbamate—GRIN2A—Activation of NMDA receptor upon glutamate binding and postsynaptic events—ACTN2—dilated cardiomyopathy	0.0133	0.0365	CbGpPWpGaD
Felbamate—GRIN2B—Post NMDA receptor activation events—ACTN2—dilated cardiomyopathy	0.0122	0.0337	CbGpPWpGaD
Felbamate—Vasculitis—Spironolactone—dilated cardiomyopathy	0.0114	0.0179	CcSEcCtD
Felbamate—GRIN2B—Activation of NMDA receptor upon glutamate binding and postsynaptic events—ACTN2—dilated cardiomyopathy	0.0113	0.031	CbGpPWpGaD
Felbamate—Cerebration impaired—Furosemide—dilated cardiomyopathy	0.0103	0.0162	CcSEcCtD
Felbamate—Hypomagnesaemia—Furosemide—dilated cardiomyopathy	0.00953	0.015	CcSEcCtD
Felbamate—Renal failure acute—Spironolactone—dilated cardiomyopathy	0.00875	0.0137	CcSEcCtD
Felbamate—Apathy—Furosemide—dilated cardiomyopathy	0.00848	0.0133	CcSEcCtD
Felbamate—Flat affect—Furosemide—dilated cardiomyopathy	0.0084	0.0132	CcSEcCtD
Felbamate—Inappropriate antidiuretic hormone secretion—Lisinopril—dilated cardiomyopathy	0.00782	0.0123	CcSEcCtD
Felbamate—GRIN2A—Reelin signaling pathway—ITGB1—dilated cardiomyopathy	0.00768	0.0211	CbGpPWpGaD
Felbamate—Ataxia—Spironolactone—dilated cardiomyopathy	0.0076	0.0119	CcSEcCtD
Felbamate—Toxic epidermal necrolysis—Spironolactone—dilated cardiomyopathy	0.00728	0.0114	CcSEcCtD
Felbamate—Gastritis—Spironolactone—dilated cardiomyopathy	0.00715	0.0112	CcSEcCtD
Felbamate—Disturbance in attention—Furosemide—dilated cardiomyopathy	0.00699	0.011	CcSEcCtD
Felbamate—GRIN2A—Alzheimers Disease—PSEN1—dilated cardiomyopathy	0.00696	0.0191	CbGpPWpGaD
Felbamate—Eosinophilia—Spironolactone—dilated cardiomyopathy	0.00691	0.0109	CcSEcCtD
Felbamate—Hypocalcaemia—Furosemide—dilated cardiomyopathy	0.00662	0.0104	CcSEcCtD
Felbamate—GRIN2B—Reelin signaling pathway—ITGB1—dilated cardiomyopathy	0.00653	0.018	CbGpPWpGaD
Felbamate—Drug interaction—Furosemide—dilated cardiomyopathy	0.00653	0.0103	CcSEcCtD
Felbamate—Hearing impaired—Furosemide—dilated cardiomyopathy	0.00636	0.00999	CcSEcCtD
Felbamate—Influenza-like symptoms—Lisinopril—dilated cardiomyopathy	0.00636	0.00999	CcSEcCtD
Felbamate—Vasculitis—Furosemide—dilated cardiomyopathy	0.00621	0.00975	CcSEcCtD
Felbamate—Stevens-Johnson syndrome—Spironolactone—dilated cardiomyopathy	0.00617	0.0097	CcSEcCtD
Felbamate—Pleural effusion—Lisinopril—dilated cardiomyopathy	0.00593	0.00932	CcSEcCtD
Felbamate—GRIN2B—Alzheimers Disease—PSEN1—dilated cardiomyopathy	0.00592	0.0163	CbGpPWpGaD
Felbamate—Otitis media—Lisinopril—dilated cardiomyopathy	0.00584	0.00917	CcSEcCtD
Felbamate—Agranulocytosis—Spironolactone—dilated cardiomyopathy	0.00581	0.00913	CcSEcCtD
Felbamate—Aplastic anaemia—Furosemide—dilated cardiomyopathy	0.00569	0.00893	CcSEcCtD
Felbamate—GRIN2A—Alzheimers Disease—PSEN2—dilated cardiomyopathy	0.00535	0.0147	CbGpPWpGaD
Felbamate—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.00529	0.0083	CcSEcCtD
Felbamate—Mental disability—Furosemide—dilated cardiomyopathy	0.00526	0.00826	CcSEcCtD
Felbamate—Thrombophlebitis—Furosemide—dilated cardiomyopathy	0.00508	0.00798	CcSEcCtD
Felbamate—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ACTN2—dilated cardiomyopathy	0.00496	0.0137	CbGpPWpGaD
Felbamate—Alopecia—Spironolactone—dilated cardiomyopathy	0.00494	0.00776	CcSEcCtD
Felbamate—Vascular purpura—Furosemide—dilated cardiomyopathy	0.00491	0.00772	CcSEcCtD
Felbamate—Drug interaction—Lisinopril—dilated cardiomyopathy	0.0049	0.0077	CcSEcCtD
Felbamate—Haemolytic anaemia—Furosemide—dilated cardiomyopathy	0.00487	0.00765	CcSEcCtD
Felbamate—Leukocytosis—Lisinopril—dilated cardiomyopathy	0.00484	0.0076	CcSEcCtD
Felbamate—Vasculitis—Lisinopril—dilated cardiomyopathy	0.00466	0.00731	CcSEcCtD
Felbamate—Dermatitis bullous—Furosemide—dilated cardiomyopathy	0.0046	0.00723	CcSEcCtD
Felbamate—Purpura—Furosemide—dilated cardiomyopathy	0.00456	0.00717	CcSEcCtD
Felbamate—GRIN2B—Alzheimers Disease—PSEN2—dilated cardiomyopathy	0.00455	0.0125	CbGpPWpGaD
Felbamate—Anaphylactoid reaction—Furosemide—dilated cardiomyopathy	0.00454	0.00714	CcSEcCtD
Felbamate—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00452	0.00709	CcSEcCtD
Felbamate—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.00441	0.00693	CcSEcCtD
Felbamate—Influenza like illness—Lisinopril—dilated cardiomyopathy	0.00441	0.00693	CcSEcCtD
Felbamate—Malaise—Spironolactone—dilated cardiomyopathy	0.00439	0.00689	CcSEcCtD
Felbamate—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00436	0.00684	CcSEcCtD
Felbamate—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ACTN2—dilated cardiomyopathy	0.00422	0.0116	CbGpPWpGaD
Felbamate—Urinary retention—Furosemide—dilated cardiomyopathy	0.00418	0.00657	CcSEcCtD
Felbamate—Discomfort—Spironolactone—dilated cardiomyopathy	0.00409	0.00643	CcSEcCtD
Felbamate—Dehydration—Furosemide—dilated cardiomyopathy	0.00409	0.00642	CcSEcCtD
Felbamate—Confusional state—Spironolactone—dilated cardiomyopathy	0.004	0.00629	CcSEcCtD
Felbamate—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.004	0.00629	CcSEcCtD
Felbamate—GRIN2A—CREB phosphorylation through the activation of Ras—RAF1—dilated cardiomyopathy	0.00398	0.0109	CbGpPWpGaD
Felbamate—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00397	0.00624	CcSEcCtD
Felbamate—GRIN2B—EPH-Ephrin signaling—PSEN2—dilated cardiomyopathy	0.00396	0.0109	CbGpPWpGaD
Felbamate—Toxic epidermal necrolysis—Furosemide—dilated cardiomyopathy	0.00396	0.00622	CcSEcCtD
Felbamate—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00389	0.00611	CcSEcCtD
Felbamate—Muscular weakness—Furosemide—dilated cardiomyopathy	0.00388	0.00609	CcSEcCtD
Felbamate—GRIN2B—EPHB-mediated forward signaling—RAC1—dilated cardiomyopathy	0.00387	0.0106	CbGpPWpGaD
Felbamate—Eosinophilia—Furosemide—dilated cardiomyopathy	0.00376	0.00591	CcSEcCtD
Felbamate—GRIN2A—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.00373	0.0103	CbGpPWpGaD
Felbamate—Pancreatitis—Furosemide—dilated cardiomyopathy	0.00373	0.00585	CcSEcCtD
Felbamate—Hepatic failure—Lisinopril—dilated cardiomyopathy	0.00367	0.00577	CcSEcCtD
Felbamate—Haemolytic anaemia—Lisinopril—dilated cardiomyopathy	0.00365	0.00574	CcSEcCtD
Felbamate—Renal failure acute—Lisinopril—dilated cardiomyopathy	0.00357	0.00561	CcSEcCtD
Felbamate—Somnolence—Spironolactone—dilated cardiomyopathy	0.00353	0.00555	CcSEcCtD
Felbamate—GRIN2B—Axon guidance—SCN5A—dilated cardiomyopathy	0.00349	0.00961	CbGpPWpGaD
Felbamate—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.00348	0.00547	CcSEcCtD
Felbamate—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.00347	0.00545	CcSEcCtD
Felbamate—Renal impairment—Lisinopril—dilated cardiomyopathy	0.00347	0.00544	CcSEcCtD
Felbamate—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.00343	0.00538	CcSEcCtD
Felbamate—Anaphylactoid reaction—Lisinopril—dilated cardiomyopathy	0.00341	0.00535	CcSEcCtD
Felbamate—GRIN2B—CREB phosphorylation through the activation of Ras—RAF1—dilated cardiomyopathy	0.00338	0.00931	CbGpPWpGaD
Felbamate—Hypoglycaemia—Lisinopril—dilated cardiomyopathy	0.00338	0.00531	CcSEcCtD
Felbamate—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.00336	0.00528	CcSEcCtD
Felbamate—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.00331	0.0052	CcSEcCtD
Felbamate—Diplopia—Lisinopril—dilated cardiomyopathy	0.0033	0.00518	CcSEcCtD
Felbamate—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.0033	0.00518	CcSEcCtD
Felbamate—GRIN2B—Developmental Biology—ZIC3—dilated cardiomyopathy	0.00329	0.00905	CbGpPWpGaD
Felbamate—GRIN2A—Post NMDA receptor activation events—RAF1—dilated cardiomyopathy	0.00327	0.00901	CbGpPWpGaD
Felbamate—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00327	0.00514	CcSEcCtD
Felbamate—Sweating—Furosemide—dilated cardiomyopathy	0.00325	0.0051	CcSEcCtD
Felbamate—Face oedema—Lisinopril—dilated cardiomyopathy	0.00318	0.005	CcSEcCtD
Felbamate—GRIN2B—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.00317	0.00873	CbGpPWpGaD
Felbamate—Agranulocytosis—Furosemide—dilated cardiomyopathy	0.00316	0.00497	CcSEcCtD
Felbamate—Urticaria—Spironolactone—dilated cardiomyopathy	0.00316	0.00496	CcSEcCtD
Felbamate—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00314	0.00493	CcSEcCtD
Felbamate—Cardiac arrest—Lisinopril—dilated cardiomyopathy	0.00314	0.00493	CcSEcCtD
Felbamate—Ataxia—Lisinopril—dilated cardiomyopathy	0.0031	0.00487	CcSEcCtD
Felbamate—Dehydration—Lisinopril—dilated cardiomyopathy	0.00307	0.00482	CcSEcCtD
Felbamate—GRIN2A—Activation of NMDA receptor upon glutamate binding and postsynaptic events—RAF1—dilated cardiomyopathy	0.00302	0.0083	CbGpPWpGaD
Felbamate—GRIN2A—Neuronal System—ABCC9—dilated cardiomyopathy	0.00298	0.00821	CbGpPWpGaD
Felbamate—Toxic epidermal necrolysis—Lisinopril—dilated cardiomyopathy	0.00297	0.00467	CcSEcCtD
Felbamate—Visual impairment—Furosemide—dilated cardiomyopathy	0.00293	0.0046	CcSEcCtD
Felbamate—Gastritis—Lisinopril—dilated cardiomyopathy	0.00292	0.00459	CcSEcCtD
Felbamate—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.00288	0.00452	CcSEcCtD
Felbamate—GRIN2A—Neuronal System—ACTN2—dilated cardiomyopathy	0.00286	0.00787	CbGpPWpGaD
Felbamate—Asthma—Lisinopril—dilated cardiomyopathy	0.00285	0.00448	CcSEcCtD
Felbamate—Eosinophilia—Lisinopril—dilated cardiomyopathy	0.00282	0.00443	CcSEcCtD
Felbamate—Pruritus—Spironolactone—dilated cardiomyopathy	0.00281	0.00441	CcSEcCtD
Felbamate—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.0028	0.00439	CcSEcCtD
Felbamate—GRIN2B—Post NMDA receptor activation events—RAF1—dilated cardiomyopathy	0.00278	0.00766	CbGpPWpGaD
Felbamate—GRIN2A—Alzheimers Disease—FAS—dilated cardiomyopathy	0.00275	0.00755	CbGpPWpGaD
Felbamate—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00272	0.00427	CcSEcCtD
Felbamate—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.00271	0.00425	CcSEcCtD
Felbamate—Dysuria—Lisinopril—dilated cardiomyopathy	0.00267	0.00419	CcSEcCtD
Felbamate—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00265	0.00416	CcSEcCtD
Felbamate—Dizziness—Spironolactone—dilated cardiomyopathy	0.00263	0.00413	CcSEcCtD
Felbamate—Flatulence—Furosemide—dilated cardiomyopathy	0.00261	0.0041	CcSEcCtD
Felbamate—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.0026	0.00409	CcSEcCtD
Felbamate—Weight increased—Lisinopril—dilated cardiomyopathy	0.00259	0.00408	CcSEcCtD
Felbamate—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00259	0.00407	CcSEcCtD
Felbamate—Weight decreased—Lisinopril—dilated cardiomyopathy	0.00258	0.00405	CcSEcCtD
Felbamate—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.00257	0.00404	CcSEcCtD
Felbamate—GRIN2B—Activation of NMDA receptor upon glutamate binding and postsynaptic events—RAF1—dilated cardiomyopathy	0.00256	0.00706	CbGpPWpGaD
Felbamate—Pneumonia—Lisinopril—dilated cardiomyopathy	0.00256	0.00402	CcSEcCtD
Felbamate—GRIN2B—Neuronal System—ABCC9—dilated cardiomyopathy	0.00254	0.00698	CbGpPWpGaD
Felbamate—Depression—Lisinopril—dilated cardiomyopathy	0.00253	0.00398	CcSEcCtD
Felbamate—Vomiting—Spironolactone—dilated cardiomyopathy	0.00253	0.00397	CcSEcCtD
Felbamate—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.00252	0.00396	CcSEcCtD
Felbamate—Rash—Spironolactone—dilated cardiomyopathy	0.0025	0.00393	CcSEcCtD
Felbamate—Dermatitis—Spironolactone—dilated cardiomyopathy	0.0025	0.00393	CcSEcCtD
Felbamate—GRIN2B—Developmental Biology—SCN5A—dilated cardiomyopathy	0.00249	0.00686	CbGpPWpGaD
Felbamate—Headache—Spironolactone—dilated cardiomyopathy	0.00249	0.00391	CcSEcCtD
Felbamate—Jaundice—Lisinopril—dilated cardiomyopathy	0.00248	0.00389	CcSEcCtD
Felbamate—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00247	0.00388	CcSEcCtD
Felbamate—Anaemia—Furosemide—dilated cardiomyopathy	0.00245	0.00384	CcSEcCtD
Felbamate—Sweating—Lisinopril—dilated cardiomyopathy	0.00244	0.00383	CcSEcCtD
Felbamate—Agitation—Furosemide—dilated cardiomyopathy	0.00243	0.00382	CcSEcCtD
Felbamate—GRIN2B—Neuronal System—ACTN2—dilated cardiomyopathy	0.00243	0.00669	CbGpPWpGaD
Felbamate—Haematuria—Lisinopril—dilated cardiomyopathy	0.00242	0.00381	CcSEcCtD
Felbamate—CYP2C19—Melatonin metabolism and effects—ADRB1—dilated cardiomyopathy	0.00242	0.00666	CbGpPWpGaD
Felbamate—Epistaxis—Lisinopril—dilated cardiomyopathy	0.0024	0.00377	CcSEcCtD
Felbamate—Sinusitis—Lisinopril—dilated cardiomyopathy	0.00238	0.00375	CcSEcCtD
Felbamate—Agranulocytosis—Lisinopril—dilated cardiomyopathy	0.00237	0.00373	CcSEcCtD
Felbamate—Leukopenia—Furosemide—dilated cardiomyopathy	0.00237	0.00372	CcSEcCtD
Felbamate—Nausea—Spironolactone—dilated cardiomyopathy	0.00236	0.00371	CcSEcCtD
Felbamate—GRIN2B—Alzheimers Disease—FAS—dilated cardiomyopathy	0.00233	0.00642	CbGpPWpGaD
Felbamate—Bradycardia—Lisinopril—dilated cardiomyopathy	0.00232	0.00365	CcSEcCtD
Felbamate—Rhinitis—Lisinopril—dilated cardiomyopathy	0.00229	0.00359	CcSEcCtD
Felbamate—Hepatitis—Lisinopril—dilated cardiomyopathy	0.00228	0.00358	CcSEcCtD
Felbamate—Hallucination—Lisinopril—dilated cardiomyopathy	0.00227	0.00357	CcSEcCtD
Felbamate—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.00226	0.00356	CcSEcCtD
Felbamate—Dry mouth—Furosemide—dilated cardiomyopathy	0.0022	0.00346	CcSEcCtD
Felbamate—Confusional state—Furosemide—dilated cardiomyopathy	0.00218	0.00342	CcSEcCtD
Felbamate—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00216	0.00339	CcSEcCtD
Felbamate—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.00216	0.00339	CcSEcCtD
Felbamate—Flushing—Lisinopril—dilated cardiomyopathy	0.00212	0.00333	CcSEcCtD
Felbamate—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00212	0.00332	CcSEcCtD
Felbamate—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00209	0.00328	CcSEcCtD
Felbamate—Anorexia—Furosemide—dilated cardiomyopathy	0.00206	0.00324	CcSEcCtD
Felbamate—Chills—Lisinopril—dilated cardiomyopathy	0.00205	0.00322	CcSEcCtD
Felbamate—Hypotension—Furosemide—dilated cardiomyopathy	0.00202	0.00317	CcSEcCtD
Felbamate—Alopecia—Lisinopril—dilated cardiomyopathy	0.00202	0.00317	CcSEcCtD
Felbamate—GRIN2B—EPH-Ephrin signaling—RAC1—dilated cardiomyopathy	0.00199	0.00548	CbGpPWpGaD
Felbamate—Flatulence—Lisinopril—dilated cardiomyopathy	0.00196	0.00307	CcSEcCtD
Felbamate—Tension—Lisinopril—dilated cardiomyopathy	0.00195	0.00306	CcSEcCtD
Felbamate—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.00195	0.00306	CcSEcCtD
Felbamate—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00194	0.00305	CcSEcCtD
Felbamate—Nervousness—Lisinopril—dilated cardiomyopathy	0.00193	0.00303	CcSEcCtD
Felbamate—Somnolence—Furosemide—dilated cardiomyopathy	0.00192	0.00302	CcSEcCtD
Felbamate—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00188	0.00295	CcSEcCtD
Felbamate—Fatigue—Furosemide—dilated cardiomyopathy	0.00186	0.00293	CcSEcCtD
Felbamate—Tremor—Lisinopril—dilated cardiomyopathy	0.00186	0.00292	CcSEcCtD
Felbamate—Pain—Furosemide—dilated cardiomyopathy	0.00185	0.0029	CcSEcCtD
Felbamate—Constipation—Furosemide—dilated cardiomyopathy	0.00185	0.0029	CcSEcCtD
Felbamate—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.00184	0.0029	CcSEcCtD
Felbamate—Anaemia—Lisinopril—dilated cardiomyopathy	0.00184	0.00288	CcSEcCtD
Felbamate—Malaise—Lisinopril—dilated cardiomyopathy	0.00179	0.00281	CcSEcCtD
Felbamate—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00178	0.0028	CcSEcCtD
Felbamate—Leukopenia—Lisinopril—dilated cardiomyopathy	0.00178	0.00279	CcSEcCtD
Felbamate—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00177	0.00278	CcSEcCtD
Felbamate—Palpitations—Lisinopril—dilated cardiomyopathy	0.00176	0.00276	CcSEcCtD
Felbamate—Cough—Lisinopril—dilated cardiomyopathy	0.00173	0.00272	CcSEcCtD
Felbamate—Urticaria—Furosemide—dilated cardiomyopathy	0.00172	0.0027	CcSEcCtD
Felbamate—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00171	0.00268	CcSEcCtD
Felbamate—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00171	0.00268	CcSEcCtD
Felbamate—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00169	0.00266	CcSEcCtD
Felbamate—Chest pain—Lisinopril—dilated cardiomyopathy	0.00169	0.00266	CcSEcCtD
Felbamate—Myalgia—Lisinopril—dilated cardiomyopathy	0.00169	0.00266	CcSEcCtD
Felbamate—Anxiety—Lisinopril—dilated cardiomyopathy	0.00169	0.00265	CcSEcCtD
Felbamate—Discomfort—Lisinopril—dilated cardiomyopathy	0.00167	0.00262	CcSEcCtD
Felbamate—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00165	0.0026	CcSEcCtD
Felbamate—Confusional state—Lisinopril—dilated cardiomyopathy	0.00163	0.00257	CcSEcCtD
Felbamate—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.00162	0.00255	CcSEcCtD
Felbamate—Oedema—Lisinopril—dilated cardiomyopathy	0.00162	0.00255	CcSEcCtD
Felbamate—Infection—Lisinopril—dilated cardiomyopathy	0.00161	0.00253	CcSEcCtD
Felbamate—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.00159	0.00249	CcSEcCtD
Felbamate—Tachycardia—Lisinopril—dilated cardiomyopathy	0.00158	0.00249	CcSEcCtD
Felbamate—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00157	0.00246	CcSEcCtD
Felbamate—GRIN2B—BDNF signaling pathway—RPS6KB1—dilated cardiomyopathy	0.00157	0.00431	CbGpPWpGaD
Felbamate—Asthenia—Furosemide—dilated cardiomyopathy	0.00155	0.00244	CcSEcCtD
Felbamate—Anorexia—Lisinopril—dilated cardiomyopathy	0.00155	0.00243	CcSEcCtD
Felbamate—Pruritus—Furosemide—dilated cardiomyopathy	0.00153	0.0024	CcSEcCtD
Felbamate—CYP2E1—Vitamin A and Carotenoid Metabolism—CD36—dilated cardiomyopathy	0.00153	0.00421	CbGpPWpGaD
Felbamate—Hypotension—Lisinopril—dilated cardiomyopathy	0.00151	0.00238	CcSEcCtD
Felbamate—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00148	0.00232	CcSEcCtD
Felbamate—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00148	0.00232	CcSEcCtD
Felbamate—GRIN2B—Axon guidance—PSEN2—dilated cardiomyopathy	0.00147	0.00405	CbGpPWpGaD
Felbamate—Insomnia—Lisinopril—dilated cardiomyopathy	0.00147	0.0023	CcSEcCtD
Felbamate—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00146	0.00229	CcSEcCtD
Felbamate—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00145	0.00227	CcSEcCtD
Felbamate—Somnolence—Lisinopril—dilated cardiomyopathy	0.00144	0.00226	CcSEcCtD
Felbamate—Dizziness—Furosemide—dilated cardiomyopathy	0.00143	0.00224	CcSEcCtD
Felbamate—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.00143	0.00224	CcSEcCtD
Felbamate—GRIN2B—BDNF signaling pathway—RAC1—dilated cardiomyopathy	0.00142	0.0039	CbGpPWpGaD
Felbamate—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00141	0.00221	CcSEcCtD
Felbamate—Fatigue—Lisinopril—dilated cardiomyopathy	0.0014	0.0022	CcSEcCtD
Felbamate—Pain—Lisinopril—dilated cardiomyopathy	0.00139	0.00218	CcSEcCtD
Felbamate—Constipation—Lisinopril—dilated cardiomyopathy	0.00139	0.00218	CcSEcCtD
Felbamate—Vomiting—Furosemide—dilated cardiomyopathy	0.00137	0.00216	CcSEcCtD
Felbamate—Rash—Furosemide—dilated cardiomyopathy	0.00136	0.00214	CcSEcCtD
Felbamate—Dermatitis—Furosemide—dilated cardiomyopathy	0.00136	0.00214	CcSEcCtD
Felbamate—Headache—Furosemide—dilated cardiomyopathy	0.00135	0.00213	CcSEcCtD
Felbamate—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.00134	0.0021	CcSEcCtD
Felbamate—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00133	0.00208	CcSEcCtD
Felbamate—Urticaria—Lisinopril—dilated cardiomyopathy	0.00129	0.00202	CcSEcCtD
Felbamate—Nausea—Furosemide—dilated cardiomyopathy	0.00128	0.00202	CcSEcCtD
Felbamate—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00128	0.00201	CcSEcCtD
Felbamate—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00128	0.00201	CcSEcCtD
Felbamate—GRIN2A—Alzheimers Disease—TNF—dilated cardiomyopathy	0.00117	0.00321	CbGpPWpGaD
Felbamate—Asthenia—Lisinopril—dilated cardiomyopathy	0.00116	0.00183	CcSEcCtD
Felbamate—Pruritus—Lisinopril—dilated cardiomyopathy	0.00115	0.0018	CcSEcCtD
Felbamate—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	0.00113	0.00311	CbGpPWpGaD
Felbamate—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.00111	0.00174	CcSEcCtD
Felbamate—CYP2C19—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.00107	0.00295	CbGpPWpGaD
Felbamate—Dizziness—Lisinopril—dilated cardiomyopathy	0.00107	0.00168	CcSEcCtD
Felbamate—GRIN2B—Developmental Biology—PSEN2—dilated cardiomyopathy	0.00105	0.00289	CbGpPWpGaD
Felbamate—Vomiting—Lisinopril—dilated cardiomyopathy	0.00103	0.00162	CcSEcCtD
Felbamate—Rash—Lisinopril—dilated cardiomyopathy	0.00102	0.00161	CcSEcCtD
Felbamate—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00102	0.0016	CcSEcCtD
Felbamate—Headache—Lisinopril—dilated cardiomyopathy	0.00102	0.0016	CcSEcCtD
Felbamate—GRIN2B—Alzheimers Disease—TNF—dilated cardiomyopathy	0.000991	0.00273	CbGpPWpGaD
Felbamate—Nausea—Lisinopril—dilated cardiomyopathy	0.000963	0.00151	CcSEcCtD
Felbamate—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	0.00096	0.00264	CbGpPWpGaD
Felbamate—GRIN2B—BDNF signaling pathway—RAF1—dilated cardiomyopathy	0.000939	0.00258	CbGpPWpGaD
Felbamate—GRIN2B—Axon guidance—ITGB1—dilated cardiomyopathy	0.000921	0.00253	CbGpPWpGaD
Felbamate—GRIN2A—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000849	0.00234	CbGpPWpGaD
Felbamate—GRIN2B—Axon guidance—RAC1—dilated cardiomyopathy	0.00074	0.00204	CbGpPWpGaD
Felbamate—GRIN2B—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000722	0.00199	CbGpPWpGaD
Felbamate—CYP2C19—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000664	0.00183	CbGpPWpGaD
Felbamate—GRIN2B—Developmental Biology—ITGB1—dilated cardiomyopathy	0.000657	0.00181	CbGpPWpGaD
Felbamate—GRIN2A—Neuronal System—RAF1—dilated cardiomyopathy	0.00065	0.00179	CbGpPWpGaD
Felbamate—CYP2C19—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000624	0.00172	CbGpPWpGaD
Felbamate—GRIN2B—Developmental Biology—CD36—dilated cardiomyopathy	0.00056	0.00154	CbGpPWpGaD
Felbamate—GRIN2B—Neuronal System—RAF1—dilated cardiomyopathy	0.000553	0.00152	CbGpPWpGaD
Felbamate—GRIN2B—Developmental Biology—RAC1—dilated cardiomyopathy	0.000528	0.00145	CbGpPWpGaD
Felbamate—GRIN2B—Axon guidance—RAF1—dilated cardiomyopathy	0.000491	0.00135	CbGpPWpGaD
Felbamate—CYP2E1—Metabolism—ANKRD1—dilated cardiomyopathy	0.000383	0.00105	CbGpPWpGaD
Felbamate—CYP2E1—Metabolism—TAZ—dilated cardiomyopathy	0.00036	0.000992	CbGpPWpGaD
Felbamate—GRIN2B—Developmental Biology—RAF1—dilated cardiomyopathy	0.00035	0.000964	CbGpPWpGaD
Felbamate—GRIN2B—Axon guidance—EGFR—dilated cardiomyopathy	0.000337	0.000926	CbGpPWpGaD
Felbamate—CYP2E1—Metabolism—SDHA—dilated cardiomyopathy	0.000326	0.000897	CbGpPWpGaD
Felbamate—CYP2C19—Metabolism—ANKRD1—dilated cardiomyopathy	0.000296	0.000814	CbGpPWpGaD
Felbamate—CYP2C19—Metabolism—TAZ—dilated cardiomyopathy	0.000278	0.000765	CbGpPWpGaD
Felbamate—CYP2C19—Metabolism—SDHA—dilated cardiomyopathy	0.000251	0.000692	CbGpPWpGaD
Felbamate—GRIN2B—Developmental Biology—EGFR—dilated cardiomyopathy	0.00024	0.000661	CbGpPWpGaD
Felbamate—GRIN2B—Developmental Biology—TNF—dilated cardiomyopathy	0.000229	0.000629	CbGpPWpGaD
Felbamate—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	0.000178	0.000489	CbGpPWpGaD
Felbamate—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	0.000167	0.00046	CbGpPWpGaD
Felbamate—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000153	0.000422	CbGpPWpGaD
Felbamate—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	0.000151	0.000416	CbGpPWpGaD
Felbamate—CYP2C19—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000149	0.000411	CbGpPWpGaD
Felbamate—CYP2C19—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000135	0.00037	CbGpPWpGaD
Felbamate—CYP2E1—Metabolism—GPX1—dilated cardiomyopathy	8.85e-05	0.000244	CbGpPWpGaD
Felbamate—CYP2E1—Metabolism—CD36—dilated cardiomyopathy	8.62e-05	0.000237	CbGpPWpGaD
Felbamate—CYP2E1—Metabolism—AGT—dilated cardiomyopathy	7.76e-05	0.000214	CbGpPWpGaD
Felbamate—CYP2C19—Metabolism—GPX1—dilated cardiomyopathy	6.83e-05	0.000188	CbGpPWpGaD
Felbamate—CYP2C19—Metabolism—CD36—dilated cardiomyopathy	6.65e-05	0.000183	CbGpPWpGaD
Felbamate—CYP2C19—Metabolism—AGT—dilated cardiomyopathy	5.99e-05	0.000165	CbGpPWpGaD
Felbamate—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	4.11e-05	0.000113	CbGpPWpGaD
Felbamate—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	4e-05	0.00011	CbGpPWpGaD
Felbamate—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	3.6e-05	9.91e-05	CbGpPWpGaD
